{"protocolSection": {"identificationModule": {"nctId": "NCT00229970", "orgStudyIdInfo": {"id": "0476-322"}, "secondaryIdInfos": [{"id": "MK0476-322"}, {"id": "2005_084"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "MK0476 Study in Adult Patients With Acute Asthma (0476-322)", "officialTitle": "MK0476 Phase II/III Placebo Controlled Double Blind Study"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-09"}, "primaryCompletionDateStruct": {"date": "2006-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-28", "studyFirstSubmitQcDate": "2005-09-28", "studyFirstPostDateStruct": {"date": "2005-09-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-05-22", "resultsFirstSubmitQcDate": "2009-05-22", "resultsFirstPostDateStruct": {"date": "2009-07-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-01-31", "lastUpdatePostDateStruct": {"date": "2022-02-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study evaluates the efficacy and safety of MK0476 intravenous administration in adult patients with acute asthma."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 225, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Placebo", "interventionNames": ["Drug: Comparator: Placebo"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "MK0476 7 mg injection", "interventionNames": ["Drug: montelukast sodium"]}, {"label": "3", "type": "EXPERIMENTAL", "description": "MK0476 14 mg injection", "interventionNames": ["Drug: montelukast sodium"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "7 mg or 14 mg single injection", "armGroupLabels": ["2", "3"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "Placebo single injection", "armGroupLabels": ["1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1)", "description": "The Time Weighed Average Changes in Forced Expiratory Volume in One Second (FEV1) from pre-allocation baseline over the first 60 minutes after study drug administration with time interval between any measurement and the measurement prior to it is used as the weighting factor", "timeFrame": "baseline over the first 60 minutes"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adult Patients With Acute Asthma Attacks\n\nExclusion Criteria:\n\n* Patient Has Any Known Or Suspected, Acute Or Chronic Cause For Their Pulmonary Symptoms Other Than Asthma (E.G., Copd, Chronic Heart Failure, Etc.)\n* Patient Has A Smoking History (20 Cigarettes Per Day) Of More Than 15 Years\n* Patient Has A Disease Of The Cardiovascular, Hepatic, Renal, Hematologic Systems, Or Other Severe Disease", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "15 Years", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "22742205", "type": "DERIVED", "citation": "Adachi M, Taniguchi H, Tohda Y, Sano Y, Ishine T, Smugar SS, Hisada S. The efficacy and tolerability of intravenous montelukast in acute asthma exacerbations in Japanese patients. J Asthma. 2012 Aug;49(6):649-56. doi: 10.3109/02770903.2012.690479. Epub 2012 Jun 28."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients with acute exacerbation of bronchial asthma received standard treatments of inhaled \u03b2-agonist or oxygen inhalation to treat the acute exacerbations during the 60 minutes in the screening period before the study randomization.", "recruitmentDetails": "Phase III.\n\nStudied period: September 12, 2005 (date study drug was first administered to first patient) to October 23, 2006 (date study drug was last administered to last patient). Study was conducted at 64 clinical sites.", "groups": [{"id": "FG000", "title": "Montelukast 7 mg", "description": "Montelukast 7 mg Intravenous Administration"}, {"id": "FG001", "title": "Montelukast 14 mg", "description": "Montelukast 14 mg Intravenous Administration"}, {"id": "FG002", "title": "Placebo", "description": "Placebo Intravenous Administration"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "78"}, {"groupId": "FG001", "numSubjects": "72"}, {"groupId": "FG002", "numSubjects": "75"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "78"}, {"groupId": "FG001", "numSubjects": "72"}, {"groupId": "FG002", "numSubjects": "75"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Montelukast 7 mg", "description": "Montelukast 7 mg Intravenous Administration"}, {"id": "BG001", "title": "Montelukast 14 mg", "description": "Montelukast 14 mg Intravenous Administration"}, {"id": "BG002", "title": "Placebo", "description": "Placebo Intravenous Administration"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "78"}, {"groupId": "BG001", "value": "72"}, {"groupId": "BG002", "value": "75"}, {"groupId": "BG003", "value": "225"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.5", "spread": "12.5"}, {"groupId": "BG001", "value": "41.5", "spread": "13.1"}, {"groupId": "BG002", "value": "42.3", "spread": "12.5"}, {"groupId": "BG003", "value": "41.4", "spread": "12.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "36"}, {"groupId": "BG003", "value": "111"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "39"}, {"groupId": "BG003", "value": "114"}]}]}]}, {"title": "Asthma Attack Severity based on Asthma Prevention and Management Guideline 2003, Japan", "description": "Mild (Peak Expiratory Flow: 70%-80%), Moderate (Peak Expiratory Flow: 50%-70%), Severe (Peak Expiratory Flow: \\<=50%) or Serious (Peak Expiratory Flow: incapable measurement, cyanosis, head trip, disturbed consciousness, incontinence or asphyxia)", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Mild", "categories": [{"measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "154"}]}]}, {"title": "Moderate", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "70"}]}]}, {"title": "Severe", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Serious", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Baseline Forced Expiratory Volume in One Second (FEV1)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.67", "spread": "0.55"}, {"groupId": "BG001", "value": "1.62", "spread": "0.59"}, {"groupId": "BG002", "value": "1.76", "spread": "0.61"}, {"groupId": "BG003", "value": "1.68", "spread": "0.58"}]}]}]}, {"title": "Duration of Asthma", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18.7", "spread": "11.5"}, {"groupId": "BG001", "value": "15.46", "spread": "11.6"}, {"groupId": "BG002", "value": "17.7", "spread": "11.7"}, {"groupId": "BG003", "value": "17.3", "spread": "11.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1)", "description": "The Time Weighed Average Changes in Forced Expiratory Volume in One Second (FEV1) from pre-allocation baseline over the first 60 minutes after study drug administration with time interval between any measurement and the measurement prior to it is used as the weighting factor", "populationDescription": "Last observed value during the 60 minutes treatment period was used in the Full Analysis Set (FAS)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liter", "timeFrame": "baseline over the first 60 minutes", "groups": [{"id": "OG000", "title": "Montelukast 7 mg", "description": "Montelukast 7 mg Intravenous Administration"}, {"id": "OG001", "title": "Montelukast 14 mg", "description": "Montelukast 14 mg Intravenous Administration"}, {"id": "OG002", "title": "Placebo", "description": "Placebo Intravenous Administration"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "lowerLimit": "0.04", "upperLimit": "0.15"}, {"groupId": "OG001", "value": "0.17", "lowerLimit": "0.12", "upperLimit": "0.23"}, {"groupId": "OG002", "value": "0.01", "lowerLimit": "-0.05", "upperLimit": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.022", "statisticalMethod": "ANCOVA", "statisticalComment": "The model included a factor for treatment and using the baseline Forced Expiratory Volume in One Second (FEV1) as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.09", "ciPctValue": "95", "ciLowerLimit": "0.01", "ciUpperLimit": "0.16"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "The model included a factor for treatment and using the baseline Forced Expiratory Volume in One Second (FEV1) as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.17", "ciPctValue": "95", "ciLowerLimit": "0.09", "ciUpperLimit": "0.24"}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "Montelukast 7 mg", "description": "Montelukast 7 mg Intravenous Administration", "seriousNumAffected": 2, "otherNumAffected": 23}, {"id": "EG001", "title": "Montelukast 14 mg", "description": "Montelukast 14 mg Intravenous Administration", "seriousNumAffected": 4, "otherNumAffected": 11}, {"id": "EG002", "title": "Placebo", "description": "Placebo Intravenous Administration", "seriousNumAffected": 4, "otherNumAffected": 13}], "seriousEvents": [{"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 75}]}, {"term": "Acute tonsillitis", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 75}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 75}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 75}]}], "otherEvents": [{"term": "Blood bilirubin increased", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 77}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 75}]}, {"term": "Blood potassium decreased", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 76}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 73}]}, {"term": "Blood urine present", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 75}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 70}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 75}]}, {"term": "Bronchitis acute", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 75}]}, {"term": "Chest pain", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 75}]}, {"term": "Glucose urine present", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 75}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 75}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 75}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 75}]}, {"term": "Protein urine present", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 75}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 70}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 75}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 75}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 77}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 70}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 75}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Japan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M274108", "name": "Montelukast", "asFound": "Conduction", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}